Chinese patent medicine for functional dyspepsia effects

Wu, Jingjie; Yao, Wei; Chen, Yaoxin; Lei, Yu; Huang, Nierui; Mei, Yingbing

doi:10.1097/md.0000000000027761

Cited by 1 publication

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, six studies (Li, 2006;Li et al, 2006;Xu, 2007;Wang, 2014;Wu, 2014;Liu and Xie, 2017) including 707 subjects were included in this systematic review (Figure 1) (Page et al, 2021).…”

Section: Study Selectionmentioning

confidence: 99%

“…All six included articles involving 707 patients were published in China between 2006 and 2017 (Table 2). For the study design, five (Li, 2006;Xu, 2007;Wang, 2014;Wu, 2014;Liu and Xie, 2017) were two-arm, parallel-design RCTs, and one (Li et al, 2006) was a three-arm trial comparing XYS, WM, and combination therapy. Among the five trials, three (Xu, 2007;Wang, 2014;Wu, 2014) compared XYS with WM, and two (Li, 2006;Liu and Xie, 2017) compared combination therapy with WM alone.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…For the study design, five (Li, 2006;Xu, 2007;Wang, 2014;Wu, 2014;Liu and Xie, 2017) were two-arm, parallel-design RCTs, and one (Li et al, 2006) was a three-arm trial comparing XYS, WM, and combination therapy. Among the five trials, three (Xu, 2007;Wang, 2014;Wu, 2014) compared XYS with WM, and two (Li, 2006;Liu and Xie, 2017) compared combination therapy with WM alone. Regarding the type of XYS, four studies (Xu, 2007;Wang, 2014;Wu, 2014;Liu and Xie, 2017) used XYS, and two (Li, 2006;Li et al, 2006) used DZXYS in the intervention group.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Among the five trials, three (Xu, 2007;Wang, 2014;Wu, 2014) compared XYS with WM, and two (Li, 2006;Liu and Xie, 2017) compared combination therapy with WM alone. Regarding the type of XYS, four studies (Xu, 2007;Wang, 2014;Wu, 2014;Liu and Xie, 2017) used XYS, and two (Li, 2006;Li et al, 2006) used DZXYS in the intervention group. Herbal prescriptions and their Frontiers in Pharmacology frontiersin.org components in the included RCTs are presented in Table 3.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Regarding the type of WM, two studies (Li et al, 2006;Wu, 2014) used Mosapride, and two (Xu, 2007;Wang, 2014) used Domperidone plus enzyme compounds in the control group to compare XYS with WM. In comparing the combination therapy and WM groups, one study (Li, 2006) compared XYS plus Tibolone versus Mosapride plus Tibolone, and the other (Liu and Xie, 2017) compared XYS plus AD versus Mosapride plus AD.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

See 4 more Smart Citations

Safety and efficacy of Xiaoyao-san for the treatment of functional dyspepsia: a systematic review and meta-analysis of randomized controlled trials

et al. 2023

View full text Add to dashboard Cite

Objective: Although Xiaoyao-san (XYS) is a popular herbal remedy for indigestion, there is insufficient evidence to recommend it as a treatment option for functional dyspepsia (FD). This review aimed to assess the safety and efficacy of XYS in patients with FD, compared to conventional Western medicine (WM).Methods: Two independent reviewers searched for randomized controlled trials (RCTs) using 11 electronic databases, including Medline and Embase, to evaluate therapeutic effects of XYS on FD up to 31 January 2023. The primary outcome was the total clinical efficacy rate (TCE), and secondary outcomes included scores of dyspepsia-related symptoms (DSS) and incidence of adverse events (AEs). The risk of bias was evaluated using the Cochrane collaboration tool, and data synthesis and subgroup analyses were performed using the Review Manager program.Results: Six studies involving 707 participants were included in the meta-analysis. XYS significantly improved TCE compared to WM (RR = 1.15, 95% CI: 1.05, 1.26, p = 0.002) with high heterogeneity (I2 = 59%, p = 0.06). Combination therapy also showed higher TCE than WM alone (RR = 1.22, 95% CI: 1.05, 1.41, p = 0.008), and the heterogeneity was low (I2 = 0%, p = 0.86). The results showed a greater reduction in DSS in the XYS and combination therapy groups than in the WM alone group (SMD = −0.72, 95% CI: −0.90, −0.53, p < 0.00001) with low heterogeneity (I2 = 44%, p = 0.15), especially for abdominal distension and upper abdominal pain. AEs occurred less frequently in the XYS and combination therapy groups than in the WM alone group (RR = 0.20, 95% CI: 0.07, 0.63, p = 0.006), and the heterogeneity was low (I2 = 45%, p = 0.18). The certainty of the evidence for each outcome was rated from “very low” to “high.”Conclusion: This review suggests that XYS is effective and safe for reducing complaints in patients with FD. However, high-quality RCTs should be conducted to establish more convincing therapeutic evidence of XYS for the treatment of FD.Systematic Review Registration:https://www.crd.york.ac.uk/prospero, CRD42020178842

show abstract

“…Finally, six studies (Li, 2006;Li et al, 2006;Xu, 2007;Wang, 2014;Wu, 2014;Liu and Xie, 2017) including 707 subjects were included in this systematic review (Figure 1) (Page et al, 2021).…”

Section: Study Selectionmentioning

confidence: 99%